Rigel Pharmaceuticals, Incorporated

Chemocentryx, Inc.

Theravance, Inc.

Theravance Biopharma R&d IP, LLC

Darren J McMurtrie

Rajinder Paul Singh

Hui Li

Vanessa Taylor

Thilo J Heckrodt

Yan Chen

Rose Yen

Penglie Zhang

Paul Ross Fatheree

Seok-Ki Choi

Roland Gendron

Robert Murray McKinnell

Sreenivas Punna

Ju Yang

Viengkham Malathong

Keith Jendza

Brooke Olson

Paul Allegretti

Kin Tso

Ryan Kelley

Christopher W Lange

Pingyu Ding

Jack Maung

Howard S Roth

Somasekhar Bhamidipati

Jeffrey Clough

Pingchen Fan

Venkat Reddy Mali

Jeffrey P McMahon

Yibin Zeng

Sambaiah Thota

Carlos A Valdez

Marina Gelman

John Yudhistir Ramphal

Andy Atuegbu

Sacha Holland

Esteban Masuda

Yu Wang

Ryan Hudson

Rebecca M Lui

Matthew Duncton

Rao Kolluri

Salvador Alvarez

Ryan J Scamp

Jeffrey Mcmahon

Compounds are provided that are useful as immunomodulators. The compounds have the Formula (I) including stereoisomers and pharmaceutically acceptable salts thereof, wherein R, R, R, R, R, R, R, R, A, Z, Xand n are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.

Heteroaryl-biphenyl amides for the treatment of PD-L1 diseases

Disclosed embodiments concern interleukin receptor associated kinases (IRAK) inhibitors, such as oxazole compounds, and compositions comprising such inhibitors. Also disclosed are methods of making and using the compounds and compositions. The disclosed compounds and/or compositions may be used to treat or prevent an IRAK-associated disease or condition.

IRAK inhibitors and method for making and using

Compounds represented by Formula (I) or (II): are provided herein, or a pharmaceutically acceptable salt, or a prodrug or bioisostere thereof; wherein R, R, R, R, R, R, R, R, R, R, R, R, R, R, R, R, R, Y, Y′, and the subscripts m and n are as defined herein.

Indanes as PD-L1 inhibitors

Heteroaryl-biphenyl amines for the treatment of PD-L1 diseases

Compounds are provided that are useful as immunomodulators. The compounds have the following Formula (II):

Immunomodulator compounds

Compounds are provided that are useful as immunomodulators. The compounds have the following Formula (I): including stereoisomers and pharmaceutically acceptable salts thereof, wherein Z, L, R, R, R, R, R, R, R, R, R, R, R, R, m and n are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.

Compounds are provided that are useful as immunomodulators. The compounds have the following Formula (I) or (II):

Macrocyclic immunomodulators

Compounds are provided that are useful as immunomodulators. The compounds have the Formula (I) including stereoisomers and pharmaceutically acceptable salts thereof, wherein R, R, R, R, R, R, R, R, R, R, R, R, Rand the subscript n are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.

Compounds for treatment of PD-L1 diseases

Compounds are provided that are useful as immunomodulators. The compounds have the following Formula (II):  including stereoisomers and pharmaceutically acceptable salts thereof, wherein R, R, R, R, R, R, R, R, R, m and n are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.

Disclosed embodiments concern novel interleukin receptor associated kinases (IRAK) inhibitors and compositions comprising such inhibitors. Also disclosed are methods of making and using the compounds and compositions. The disclosed compounds and/or compositions may be used to treat or prevent an IRAK-associated disease or condition.

Pyrazole compounds and methods for making and using the compounds

Compounds are provided that are useful as immunomodulators. The compounds have the Formula (I) including stereoisomers and pharmaceutically acceptable salts thereof, wherein R, R, R, R, R, R, R, R, R, R, R, R, A, Z, Xand n are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.

Triaryl compounds for treatment of PD-L1 diseases

Disclosed are compounds of formula I, compositions containing them, and methods of use for the compounds and compositions in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK 2 and JAK3, are therapeutically useful. Also disclosed are methods of making the compounds.

Compositions and methods for inhibition of the JAK pathway

Compounds are provided that are useful as immunomodulators. The compounds have the following Formula (I) or (II): 

Growing community of inventors

Sunnyvale, CA, United States of America

Darren J McMurtrie